Skip to main content

Table 1 Sensitivity of commercial CCP2 test and noncommercial CFFCP enzyme-linked immunosorbent assays in different rheumatoid arthritis populations and control groups

From: Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis

Population

n

CFFCP1

CFFCP2

CFFCP3

CCP2

Rheumatoid arthritis

322

232 (72%)

251 (78%)

230 (71.4%)

238 (73.9%)

   RF+

226

188 (83.2%)

199 (88.1%)

192 (85%)

199 (88.1%)

   RF-a

95

43 (45.3%)

52 (54.7%)

38 (40%)

39 (41.1%)

   Early

134

102 (76.1%)

104 (77.6%)

99 (73.9%)

99 (73.9%)

   Anti-TNF-α treatment

78

56 (71.8%)

62 (79.5%)

61 (78.2%)

62 (79.5%)

Healthy blood donors

307

6 (2%)

6 (2%)

6 (2%)

6 (2%)

Systemic lupus erythematosus

119

11 (9.2%)

11 (9.2%)

9 (7.6%)

9 (7.6%)

Psoriatic arthritis

133

6 (4.5%)

13 (9.8%)

2 (1.5%)

4 (3%)

Hepatitis C virus infection

84

12 (14.3%)

2 (2.4%)

2 (2.4%)

1 (1.2%)

  1. aP < 0.0001 for all autoantibodies in comparison with RF+ rheumatoid arthritis. In one RA patient, RF status was not available. RF = rheumatoid factor; TNF = tumor necrosis factor.